Global Pharmaceutical Continuous Manufacturing Market Report 2024, Forecast To 2033
8 Mar, 2024
The pharmaceutical continuous manufacturing market has seen rapid expansion, rising from $2.26 billion in 2023 to $2.5 billion in 2024, with a compound annual growth rate (CAGR) of 10.5%. This growth is attributed to factors such as quality and efficiency improvements and regulatory support. Moving forward, the market is projected to reach $3.71 billion by 2028, with a CAGR of 10.4%, fueled by trends such as increasing generic drug production and a focus on patient-centric approaches. Major trends in the forecast period include the adoption of continuous manufacturing and the integration of process analytical technology.
Global Pharmaceutical Continuous Manufacturing Market Key Driver
The pharmaceutical continuous manufacturing market is witnessing growth propelled by the increasing prevalence of chronic ailments globally. Chronic diseases, lasting for a year or longer and requiring ongoing medical treatment, represent a significant burden on healthcare systems. According to the National Association of Chronic Disease Directors (NACDD), almost 60% of adult Americans have at least one chronic disease, with annual costs projected to reach $2 trillion by 2030. This growing prevalence underscores the need for efficient and cost-effective manufacturing processes, driving demand for continuous manufacturing in the pharmaceutical sector.
Get A Free Sample Of The Global Pharmaceutical Continuous Manufacturing Market ReportGlobal Pharmaceutical Continuous Manufacturing Market Segments
The pharmaceutical continuous manufacturing market covered in this report is segmented –
1) Product:Integrated Continuous System, Control And Software, Semi-Continuous System
2) Therapeutics Type:Large Molecule, Small Molecule
3) Formulation:Solid Formation, Liquid And Semi-Solid Formation
4) Application:Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing
5) End-Users:Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users
By Geography: The countries covered in the pharmaceutical continuous manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Pharmaceutical Continuous Manufacturing Industry Players
Pfizer Inc.; Robert Bosch GmbH; Siemens AG; Novartis AG; Thermo Fisher Scientific Inc.; GlaxoSmithKline Plc.; Eli Lilly and Company; Corning Inc.; Vertex Pharmaceuticals; Lonza Group Ltd.; GEA Group AG; Catalent Inc.; Mettler Toledo; Patheon; Cytiva; Samsung Biologics Co.Ltd.; WuXi Biologics; Syntegon Technology GmbH; Coperion GmbH; Hosokawa Micron Group; FUJIFILM Diosynth Biotechnologies; Leistritz AG; Glatt GmbH; Freund-Vector Corp.; SK biotek Co. Ltd.; Gericke AG; GEBRÜDER LÖDIGE MASCHINENBAU GmbH; Munson Machinery Company Inc.; L.B. Bohle Maschinen und Verfahren GmbH; KORSCH AG; Chemtrix BV
Get The Full Global Pharmaceutical Continuous Manufacturing Market Report
Pharmaceutical Continuous Manufacturing Market Overview
Pharmaceutical continuous manufacturing (PCM) is a process of producing pharmaceutical goods from start to finish on a single, straight production line. It is utilized to manufacture active pharmaceutical components by flow chemical transformations and multistep syntheses that can operate for a longer length of time, potentially reducing medicine shortages.